Neuroimmune Tau Mechanisms: Their Role in the Progression of Neuronal Degeneration
- PMID: 29570615
- PMCID: PMC5979395
- DOI: 10.3390/ijms19040956
Neuroimmune Tau Mechanisms: Their Role in the Progression of Neuronal Degeneration
Abstract
Progressive neurodegenerative pathologies in aged populations are an issue of major concern worldwide. The microtubule-associated protein tau is able to self-aggregate to form abnormal supramolecular structures that include small oligomers up to complex polymers. Tauopathies correspond to a group of diseases that share tau pathology as a common etiological agent. Since microglial cells play a preponderant role in innate immunity and are the main source of proinflammatory factors in the central nervous system (CNS), the alterations in the cross-talks between microglia and neuronal cells are the main focus of studies concerning the origins of tauopathies. According to evidence from a series of studies, these changes generate a feedback mechanism reactivating microglia and provoking constant cellular damage. Thus, the previously summarized mechanisms could explain the onset and progression of different tauopathies and their functional/behavioral effects, opening the window towards an understanding of the molecular basis of anomalous tau interactions. Despite clinical and pathological differences, increasing experimental evidence indicates an overlap between tauopathies and synucleinopathies, considering that neuroinflammatory events are involved and the existence of protein misfolding. Neurofibrillary tangles of pathological tau (NFT) and Lewy bodies appear to coexist in certain brain areas. Thus, the co-occurrence of synucleinopathies with tauopathies is evidenced by several investigations, in which NFT were found in the substantia nigra of patients with Parkinson's disease, suggesting that the pathologies share some common features at the level of neuroinflammatory events.
Keywords: Alzheimer’s disease; inflammation; molecular functions; molecular networks; neuroimmunomodulation; tau protein; tauopathies.
Conflict of interest statement
The authors declare no conflict of interest. The funding sponsors had no role in the design of the study and in the writing of the manuscript and no role at all in the decision to publish the results.
Figures

Similar articles
-
Tau alteration and neuronal degeneration in tauopathies: mechanisms and models.Biochim Biophys Acta. 2005 Jan 3;1739(2-3):331-54. doi: 10.1016/j.bbadis.2004.06.018. Biochim Biophys Acta. 2005. PMID: 15615650 Review.
-
Protein aggregation and neurodegeneration in prototypical neurodegenerative diseases: Examples of amyloidopathies, tauopathies and synucleinopathies.Prog Neurobiol. 2017 Aug;155:171-193. doi: 10.1016/j.pneurobio.2015.07.003. Epub 2015 Jul 21. Prog Neurobiol. 2017. PMID: 26209472 Review.
-
[Neuropathology of tauopathy].Brain Nerve. 2013 Dec;65(12):1445-58. Brain Nerve. 2013. PMID: 24323931 Review. Japanese.
-
Tau pathology in Alzheimer disease and other tauopathies.Biochim Biophys Acta. 2005 Jan 3;1739(2-3):198-210. doi: 10.1016/j.bbadis.2004.09.008. Biochim Biophys Acta. 2005. PMID: 15615638 Review.
-
Systemic and network functions of the microtubule-associated protein tau: Implications for tau-based therapies.Mol Cell Neurosci. 2017 Oct;84:132-141. doi: 10.1016/j.mcn.2017.03.003. Epub 2017 Mar 17. Mol Cell Neurosci. 2017. PMID: 28318914 Review.
Cited by
-
The neuroprotective effects of glucagon-like peptide 1 in Alzheimer's and Parkinson's disease: An in-depth review.Front Neurosci. 2022 Sep 1;16:970925. doi: 10.3389/fnins.2022.970925. eCollection 2022. Front Neurosci. 2022. PMID: 36117625 Free PMC article. Review.
-
Neuroinflammation as a Common Feature of Neurodegenerative Disorders.Front Pharmacol. 2019 Sep 12;10:1008. doi: 10.3389/fphar.2019.01008. eCollection 2019. Front Pharmacol. 2019. PMID: 31572186 Free PMC article. Review.
-
Tocotrienol Rich Fraction Supplementation Modulate Brain Hippocampal Gene Expression in APPswe/PS1dE9 Alzheimer's Disease Mouse Model.J Alzheimers Dis. 2019;70(s1):S239-S254. doi: 10.3233/JAD-180496. J Alzheimers Dis. 2019. PMID: 30507571 Free PMC article.
-
Immunoproteasome Subunit Low Molecular Mass Peptide 2 (LMP2) Deficiency Ameliorates LPS/Aβ1-42-Induced Neuroinflammation.Mol Neurobiol. 2024 Jan;61(1):28-41. doi: 10.1007/s12035-023-03564-9. Epub 2023 Aug 12. Mol Neurobiol. 2024. PMID: 37568045
-
Acylated Ghrelin as a Multi-Targeted Therapy for Alzheimer's and Parkinson's Disease.Front Neurosci. 2020 Dec 14;14:614828. doi: 10.3389/fnins.2020.614828. eCollection 2020. Front Neurosci. 2020. PMID: 33381011 Free PMC article. Review.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical